XML 22 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Net revenues $ 14,925 $ 15,878 $ 16,659
Cost of sales 7,952 8,284 8,933
Gross profit 6,973 7,594 7,726
Research and development expenses, net 838 967 997
Selling and marketing expenses 2,265 2,429 2,498
General and administrative expenses 1,180 1,099 1,173
Intangible assets impairments 355 424 1,502
Goodwill impairment 2,045 0 4,628
Other asset impairments, restructuring and other items 414 341 479
Legal settlements and loss contingencies 2,082 717 60
Other income (107) (98) (40)
Operating (loss) income (2,099) 1,716 (3,572)
Financial expenses – net 966 1,058 834
Income (loss) before income taxes (3,065) 658 (4,406)
Income taxes (benefit) (638) 211 (168)
Share in (profits) losses of associated companies – net (21) (9) (138)
Net income (loss) (2,406) 456 (4,099)
Net income (loss) attributable to non-controlling interests (53) 39 (109)
Net income (loss) attributable to Teva $ (2,353) $ 417 $ (3,990)
Earnings (loss) per share attributable to ordinary shareholders:      
Basic $ (2.12) $ 0.38 $ (3.64)
Diluted $ (2.12) $ 0.38 $ (3.64)
Weighted average number of shares (in millions):      
Basic 1,110 1,102 1,095
Diluted 1,110 1,107 1,095